Donepezil Hydrochloride Tablet, Film Coated
Product Images NDC 71205-948

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 71205-948). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

01 (30406488 Figure 01)

Chemical structure of Donepezil Hydrochloride showing its molecular arrangement, including two methoxy groups attached to a benzene ring, a piperidine ring, and a benzyl group, with the hydrochloride component indicated.*

FDA Label Image

Figure2 (30406488 Figure 02)

A line graph depicting ADAS-cog change from baseline (Mean ± SE) over weeks of drug treatment, comparing Donepezil Hydrochloride tablets at 10 mg/day and 5 mg/day doses versus placebo. The y-axis ranges from clinical improvement to clinical decline, illustrating cognitive changes across treatment periods up to 30 weeks.*

FDA Label Image

Figure-03 (30406488 Figure 03)

A line graph showing the cumulative percentage of patients versus change from baseline in ADAS-cog scores for Donepezil Hydrochloride Tablets at 5 mg/day and 10 mg/day compared to placebo. The graph includes markers at 7 points, 4 points, and no change, as well as a small table summarizing treatment group percentages at these points.*

FDA Label Image

Figure-04 (30406488 Figure 04)

A bar graph comparing the percentage of patients by CIBIC-plus Rating categories for Donepezil Hydrochloride Tablets at 10 mg/day and 5 mg/day, as well as a placebo group. The categories range from Markedly Improved to Markedly Worse, showing distribution of patient responses across treatment and placebo groups.*

FDA Label Image

Figure-05 (30406488 Figure 05)

A line graph showing the mean change from baseline in ADAS-cog scores over 12 weeks of drug treatment followed by placebo. It compares Donepezil Hydrochloride tablets at 10 mg/day and 5 mg/day doses versus placebo, indicating clinical improvement or decline. Data points include error bars representing standard error.*

FDA Label Image

Figure-06 (30406488 Figure 06)

A cumulative percentage of patients graph showing the change from baseline in ADAS-cog scores. The graph compares three groups: Placebo, Donepezil Hydrochloride Tablets 5 mg/day, and Donepezil Hydrochloride Tablets 10 mg/day, with data points for 7 points, 4 points, and no change. A small data table summarizes percentage changes within each treatment group for -7, -4, and 0 point changes.*

FDA Label Image

Figure-07 (30406488 Figure 07)

Bar chart depicting patient response percentages across different improvement categories (Markedly Improved to Markedly Worse) for Donepezil Hydrochloride 10 mg/day, 5 mg/day tablets, and placebo groups. The chart compares the proportions of patients experiencing various degrees of change in condition among the three groups.*

FDA Label Image

08 (30406488 Figure 08)

A line graph showing the SIB change from baseline mean (±SE) over 6 months of drug treatment comparing Donepezil Hydrochloride Tablets 10 mg/day and placebo. The y-axis represents clinical improvement or decline, and the x-axis shows treatment duration in months. Donepezil shows clinical improvement while placebo shows clinical decline.*

FDA Label Image

09 (30406488 Figure 09)

Cumulative percentage of patients chart showing SIB change from baseline comparing Donepezil Hydrochloride Tablets 10 mg/day with placebo. The X-axis represents the SIB change from baseline, and the Y-axis shows the cumulative percentage of patients. Data points for Donepezil are represented by filled circles, and placebo by open squares.*

FDA Label Image

10 (30406488 Figure 10)

Graph showing mean change from baseline in ADCS-ADL scores over 6 months of drug treatment, comparing Donepezil Hydrochloride Tablets 10 mg/day with placebo. The y-axis depicts ADCS-ADL change with clinical improvement at the top and decline at the bottom; the x-axis shows months of treatment at 0, 3, and 6 months. Results indicate a smaller decline in ADCS-ADL scores with Donepezil compared to placebo over time.*

FDA Label Image

11 (30406488 Figure 11)

A line graph comparing the cumulative percentage of patients over varying ADCS-ADL change from baseline scores between Donepezil Hydrochloride tablets 10 mg/day and placebo. The X-axis represents the change from baseline, ranging from +20 to -20, and the Y-axis shows the cumulative percentage of patients from 0 to 100%. Two lines depict Donepezil Hydrochloride (solid circles) and placebo (open squares), showing a distribution shift between the two groups.*

FDA Label Image

12 (30406488 Figure 12)

A line graph showing SIB Change from Baseline (LS mean ± SE) over 24 weeks of drug treatment comparing Donepezil Hydrochloride Tablets 23 mg/day and 10 mg/day. The vertical axis ranges from -3 to 5 indicating clinical decline to improvement, with baseline marked at 0. Two lines represent different doses, indicating changes over time with error bars at multiple intervals.*

FDA Label Image

13 (30406488 Figure 13)

A cumulative percentage of patients chart comparing SIB score changes from baseline for Donepezil Hydrochloride Tablets 23 mg/day and 10 mg/day. The x-axis shows SIB change from baseline, while the y-axis shows the cumulative percentage of patients. Two plotted lines represent the different dosage groups.*

FDA Label Image

14 (30406488 Figure 14)

A bar graph comparing the percentage of patients for Donepezil Hydrochloride Tablets at 23 mg/day and 10 mg/day across various CIBIC-plus ratings, including Markedly Improved, Moderately Improved, Minimally Improved, No Change, Minimally Worse, Moderately Worse, and Markedly Worse.*

FDA Label Image

15 (30406488 Figure 15)

FDA Label Image

71205-948-30 (30406488 Figure 16)

Label for Donepezil Hydrochloride 23 mg tablets, film-coated and round, with 'T004' printed in black on one side. The package contains 30 tablets. Manufactured by TWi Pharmaceuticals, Inc., Taoyuan City, Taiwan, and relabeled by Proficient Rx LP in Thousand Oaks, CA. The label includes storage instructions and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.